GlobeNewsWire
10 Jun 2026, 19:32 UTC · 4h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Cosmos Health's subsidiary, Cana Laboratories, secured a three-year contract to manufacture 3.9 million units of VASCLOR GEST progesterone pessaries for Verisfield S.A. — Guarantees a steady volume of production and revenue over three years, providing predictable cash flow for the contract manufacturing segment.
+0.40The new agreement expands Cosmos Health's capabilities and order book into the women's health and reproductive medicine therapeutic areas. — Diversification into new therapeutic categories reduces client concentration risk and opens potential for further growth in a specialized medical niche.
+0.20CEO Greg Siokas identifies the contract manufacturing division as a high-margin segment of the company's business. — Indicates that growth in this specific division is likely to have a positive accretive effect on the company's overall profit margins.
+0.15Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company secured a lucrative three-year contract manufacturing agreement, expanding its customer base and diversifying into women's health.
Go deeper
You just saw which tickers this one story hits. A free account turns that into a standing screen: the movers delivered on schedule, before the chart catches up.
On this page · free
In the platform
Free account, 30 seconds. No credit card. Covers all 10 tickers this story moves.
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Screener bridge
Catch the names this kind of story moves — before the chart does.
Get the full NIS Momentum results every Friday at 4PM ET — free via email or Telegram.
GlobeNewsWire
12h ago
